AIM ImmunoTech (NYSEAMERICAN:AIM – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.12), FiscalAI reports. The company had revenue of $0.02 million during the quarter.
AIM ImmunoTech Stock Performance
AIM stock traded down $0.00 during trading on Friday, hitting $0.14. The stock had a trading volume of 139,273 shares, compared to its average volume of 10,596,602. The stock has a market cap of $4.38 million, a price-to-earnings ratio of -0.05 and a beta of 1.32. The company’s 50 day moving average price is $0.18 and its two-hundred day moving average price is $0.45. AIM ImmunoTech has a 1-year low of $0.12 and a 1-year high of $1.88.
About AIM ImmunoTech
AIM ImmunoTech Inc. is a biotechnology company focused on developing and commercializing immune-based therapies for cancer, chronic disorders and infectious diseases. The company’s lead product candidate is Ampligen (rintatolimod), an investigational double-stranded RNA immunomodulator designed to stimulate components of the immune system. Ampligen has been studied in conditions including myalgic encephalomyelitis/chronic fatigue syndrome, certain cancers and viral infections, although it is not broadly approved by the U.S. Food and Drug Administration.
Further Reading
- Five stocks we like better than AIM ImmunoTech
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.
